“NEW YORK (Reuters Health) – New age-related macular degeneration (AMD) develops in about a quarter of fellow eyes to those treated for neovascular AMD with intravitreal anti-VEGF agents, according to a post hoc analysis of the VIEW 1 and VIEW 2 studies.”
“The high risk for fellow eye conversion in patients with neovascular AMD in one eye highlights the need to explore prophylactic treatments beyond the rather modest protection provided by the Age-Related Eye Disease Study 2 nutritional supplements,” Dr. Freund said. “Until more effective preventative treatment exists, there is an unmet need for more reliable home-based monitoring systems.” (Click here to read the entire article)